Almac Launches SupplyTraQ™ Technology Solution
Complete the form below to unlock access to ALL audio articles.
Almac has announced the launch of SupplyTraQ™, a web-based drug accountability and reconciliation tool that improves clinical trial drug supply management and simplifies post-trial administration.
Compatible with IXRS®, the company’s industry-leading IVR/IWR technology, SupplyTraQ enables users to capture drug supply data in real-time and improve the accuracy of the supply management process.
SupplyTraQ accommodates multiple protocols and study designs, offering users a cost-effective method of supporting clinical trials and consolidating trial supply records.
Built-in validation checks flag discrepancies as soon as they occur, enabling more accurate data collection and reporting at trial sites and distribution depots.
“SupplyTraQ simplifies the drug accountability, reconciliation, and destruction process - all essential components of clinical trial management,” says Charlie Morris, Vice President, New Products & Services.
Morris continued, “By having a real-time view of drug returns, transfers and destruction at both the site and depot levels for discrete drugs, trial managers can take better control of their drug supply and produce higher-quality data.”
SupplyTraQ provides a lower-cost alternative to the manual drug supply management processes used by many clinical trial professionals.
Alerts and user-defined search capabilities support fast identification - and resolution - of discrepancies and help to accelerate accountability, reconciliation, and destruction activities.
SupplyTraQ further streamlines the process by facilitating authorized, remote review of inventories, enabling site monitors to more efficiently manage their time and site visit schedule.
The tool is also adaptable to company-specific processes and trial requirements, which can vary widely depending on study complexity and scope.
When used in conjunction with Almac’s IXRS technology, supply management and patient events are completely integrated and yield a holistic view of the drug kit lifecycle.
